CHANCE - Candesartan in Hypertrophic Cardiomyopathy

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The primary hypothesis of the study is that treatment with AT1-R antagonist in patients with nonobstructive form of HCM will be first save, second will cause regression of myocardial hypertrophy.

• Phase: Phase 2

Details

• Lead Sponsor: Charles University, Czech Republic
• Collaborator: AstraZeneca
• Treatments: Candesartan; Candesartan cilexetil

Criteria

Inclusion Criteria:

• HCM defined on the basis of echocardiographic criteria showing a nondilated, hypertrophied left ventricle (any wall thickness > 15 mm) in the absence of known causes of LV hypertrophy hypertension or valvular disease

Exclusion Criteria:

• Hypertrophic obstructive cardiomyopathy defined as presence of resting gradient in left ventricular outflow tract ³30 mmHg or in righ ventricular outflow tract ³15 mmHg at Doppler echocardiography;

• Atrial fibrillation;

• Treatment with ACE inhibitors or AT1-R antagonists any time in the past;

• Contraindications to AT1-R antagonists;

• Coronary artery disease, renal failure, hepatic disorders or serious intercurrent illness limiting survival; and

• Poor echocardiographic image quality.